Posted by Michael Wonder on 08 Sep 2019
ICER to assess treatments for cystic fibrosis
6 September 2019 - Report will be subject of California Technology Assessment Forum meeting in April 2020; open Input now being accepted until 25 September 2019.
The Institute for Clinical and Economic Review (ICER) will assess the comparative clinical effectiveness and value of therapies for cystic fibrosis (CF). The report will focus on elexacaftor/tezacaftor/ivacaftor (Vertex Pharmaceuticals), which has a PDUFA date of 19 March 2020. ICER also will examine any new data that has become available since its May 2018 review of three other CF treatments already approved by the FDA: tezacaftor/ivacaftor (Symdeko, Vertex), lumacaftor/ivacaftor (Orkambi, Vertex), and ivacaftor (Kalydeco, Vertex).
The report will be reviewed during a public meeting of the California Technology Assessment Forum (CTAF) in April 2020.
